Business · 26/01/2024Updated: 10/17/2026 · 1 min read
FDA Releases Final Document on Best Practices for Postmarketing Safety Surveillance of Human Drug and Biological Products
Summary
The Food and Drug Administration (FDA) has made publicly available a final document outlining risk-based principles for postmarketing safety surveillance of human drug and biological products, in response to the 21st Century Cures Act requirements.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →